ADMA Biologics Inc (ADMA, Financial) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $105.85 million, and the earnings are expected to come in at $0.11 per share. The full year 2024's revenue is expected to be $406.09 million and the earnings are expected to be $0.43 per share. More detailed estimate data can be found on the Forecast page.
ADMA Biologics Inc (ADMA, Financial) Estimates Trends
Over the past 90 days, revenue estimates for ADMA Biologics Inc (ADMA) for the full year 2024 have increased from $357.5 million to $406.09 million and for 2025 from $414.48 million to $459.22 million. Similarly, earnings estimates have risen from $0.32 per share to $0.43 per share for the full year 2024, and from $0.52 per share to $0.66 per share for 2025.
ADMA Biologics Inc (ADMA, Financial) Reported History
In the previous quarter of June 30, 2024, ADMA Biologics Inc's (ADMA) actual revenue was $107.19 million, which beat analysts' revenue expectations of $86.413 million by 24.04%. ADMA Biologics Inc's (ADMA) actual earnings were $0.13 per share, which beat analysts' earnings expectations of $0.073 per share by 78.08%. After releasing the results, ADMA Biologics Inc (ADMA) was up by 30.93% in one day.
ADMA Biologics Inc (ADMA, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 5 analysts, the average target price for ADMA Biologics Inc (ADMA) is $18.65 with a high estimate of $20 and a low estimate of $17.23. The average target implies a downside of -0.98% from the current price of $18.83.
Based on GuruFocus estimates, the estimated GF Value for ADMA Biologics Inc (ADMA, Financial) in one year is $7.7, suggesting a downside of -59.11% from the current price of $18.83.
Based on the consensus recommendation from 5 brokerage firms, ADMA Biologics Inc's (ADMA, Financial) average brokerage recommendation is currently 1.8, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
